Prospective, double-blind, randomized trial of teicoplanin versus vancomycin for the therapy of vascular access-associated bacteremia caused by gram-positive pathogens

Journal of Infection and Chemotherapy

Volumn 5, Issue 4, 1999, Pages 208-212

  Rolston, Kenneth V I ^a   Chow, Anthony W ^a,b   Bodey, Gerald P ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Gram positive pathogens; Staphylococcus aureus; Teicoplanin; Vancomycin; Vascular access associated bacteremia

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFTAZIDIME; GENTAMICIN; METRONIDAZOLE; NETILMICIN; PIPERACILLIN; TEICOPLANIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; FEMALE; GRAM POSITIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VASCULAR ACCESS;

EID: 0033401897     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101560050037     Document Type: Article

References (15)

1. Eykyn SJ. Infection and intravenous catheters. J Antimicrob Chemother 1988;22:397-401.
2. Raad I, Alrahwan A, Rolston K. Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin Infect Dis 1998;26:1182-7.
3. Davis RL, Smith AL, Koup JR. The "red man" syndrome and slow infusion of vancomycin. Ann Intern Med 1986;104:285-6.
4. Neu HC, Labthavkinul P. In vitro activity of teichomycin compared with those of other antibiotics. Antimicrob Agents Chemother 1983;24:425-8.
5. Williams AH, Gryneberg RN. Teicoplanin revisited. J Antimicrob Chemother 1988;22:397-401.
6. Fietta A, Bersani C, Mangiarotti P, Sacchi F, Gialdroni Grassi G. Interference of techomycin and vancomycin with the bactericidal activity of human phagocytes. In: Proceedings of the Third Mediterranean Congress of Chemotherapy, vol 9, 1982:152-4.
7. Erickson RC, Hildebrand AR, Huffman PF, Gibson CB. A sensitive bioassay for teicoplanin in serum in the presence or absence of other antibiotics. Diagn Microbiol Infect Dis 1989;12:235-41.
8. Shuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Biopharm 1987;15:657-80.
9. Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986:11:257-82.
10. Babul N, Pasko M. Teicoplanin: a new glycopeptide antibiotic complex. Drug Intelligence Clin Pharm 1988;22:218-26.
11. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996:37:209-22.
12. Smith SR, Cheesbrough J, Spearing J, Davies JM. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother 1989;33:1193-7.
13. Goldstein FW, Coutrot A, Sieffer A, Acar JF. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother 1990;34:899-900.
14. Leclercq R, Derlot E, Weber J. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1983;33:10-15.
15. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.